Switch theme
Sign up to access all valuation multiples
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
1980
83
LTM Revenue $36.7M
LTM EBITDA -$2.2M
$156M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
KORU Medical Systems has a last 12-month revenue (LTM) of $36.7M and a last 12-month EBITDA of -$2.2M.
In the most recent fiscal year, KORU Medical Systems achieved revenue of $33.6M and an EBITDA of -$5.6M.
KORU Medical Systems expects next 12-month revenue of XXX and NTM EBITDA of XXX
See KORU Medical Systems valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $36.7M | XXX | $33.6M | XXX | XXX | XXX |
| Gross Profit | $23.0M | XXX | $21.3M | XXX | XXX | XXX |
| Gross Margin | 63% | XXX | 63% | XXX | XXX | XXX |
| EBITDA | -$2.2M | XXX | -$5.6M | XXX | XXX | XXX |
| EBITDA Margin | -6% | XXX | -17% | XXX | XXX | XXX |
| EBIT | -$5.6M | XXX | -$6.4M | XXX | XXX | XXX |
| EBIT Margin | -15% | XXX | -19% | XXX | XXX | XXX |
| Net Profit | -$5.1M | XXX | -$6.1M | XXX | XXX | XXX |
| Net Margin | -14% | XXX | -18% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, KORU Medical Systems's stock price is $3.
KORU Medical Systems has current market cap of $161M, and EV of $156M.
See KORU Medical Systems trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $156M | $161M | XXX | XXX | XXX | XXX | $-0.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, KORU Medical Systems has market cap of $161M and EV of $156M.
KORU Medical Systems's trades at 4.6x EV/Revenue multiple, and -28.1x EV/EBITDA.
Equity research analysts estimate KORU Medical Systems's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
KORU Medical Systems has a P/E ratio of -31.7x.
See valuation multiples for KORU Medical Systems and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $161M | XXX | $161M | XXX | XXX | XXX |
| EV (current) | $156M | XXX | $156M | XXX | XXX | XXX |
| EV/Revenue | 4.2x | XXX | 4.6x | XXX | XXX | XXX |
| EV/EBITDA | -71.5x | XXX | -28.1x | XXX | XXX | XXX |
| EV/EBIT | -28.1x | XXX | -24.2x | XXX | XXX | XXX |
| EV/Gross Profit | 6.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -31.7x | XXX | -26.5x | XXX | XXX | XXX |
| EV/FCF | -120.6x | XXX | -93.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKORU Medical Systems's last 12 month revenue growth is 15%
KORU Medical Systems's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.
KORU Medical Systems's rule of 40 is -18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
KORU Medical Systems's rule of X is 32% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for KORU Medical Systems and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Margin | -6% | XXX | -17% | XXX | XXX | XXX |
| EBITDA Growth | -116% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -18% | XXX | -1% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 32% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 83% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
KORU Medical Systems acquired XXX companies to date.
Last acquisition by KORU Medical Systems was XXXXXXXX, XXXXX XXXXX XXXXXX . KORU Medical Systems acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was KORU Medical Systems founded? | KORU Medical Systems was founded in 1980. |
| Where is KORU Medical Systems headquartered? | KORU Medical Systems is headquartered in United States of America. |
| How many employees does KORU Medical Systems have? | As of today, KORU Medical Systems has 83 employees. |
| Who is the CEO of KORU Medical Systems? | KORU Medical Systems's CEO is Ms. Linda M. Tharby. |
| Is KORU Medical Systems publicy listed? | Yes, KORU Medical Systems is a public company listed on NAS. |
| What is the stock symbol of KORU Medical Systems? | KORU Medical Systems trades under KRMD ticker. |
| When did KORU Medical Systems go public? | KORU Medical Systems went public in 1996. |
| Who are competitors of KORU Medical Systems? | Similar companies to KORU Medical Systems include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of KORU Medical Systems? | KORU Medical Systems's current market cap is $161M |
| What is the current revenue of KORU Medical Systems? | KORU Medical Systems's last 12 months revenue is $36.7M. |
| What is the current revenue growth of KORU Medical Systems? | KORU Medical Systems revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of KORU Medical Systems? | Current revenue multiple of KORU Medical Systems is 4.2x. |
| Is KORU Medical Systems profitable? | Yes, KORU Medical Systems is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of KORU Medical Systems? | KORU Medical Systems's last 12 months EBITDA is -$2.2M. |
| What is KORU Medical Systems's EBITDA margin? | KORU Medical Systems's last 12 months EBITDA margin is -6%. |
| What is the current EV/EBITDA multiple of KORU Medical Systems? | Current EBITDA multiple of KORU Medical Systems is -71.5x. |
| What is the current FCF of KORU Medical Systems? | KORU Medical Systems's last 12 months FCF is -$1.3M. |
| What is KORU Medical Systems's FCF margin? | KORU Medical Systems's last 12 months FCF margin is -4%. |
| What is the current EV/FCF multiple of KORU Medical Systems? | Current FCF multiple of KORU Medical Systems is -120.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
